Skip to main content Skip to navigation
BV421 Mouse Anti-Human CCRL1
Product Details
Down Arrow Up Arrow

BD OptiBuild™
Human (Tested in Development)
Mouse BALB/c IgG2b, κ
Human CCX-CKR gene-based immunization
Flow cytometry (Qualified)
0.2 mg/ml
Aqueous buffered solution containing ≤0.09% sodium azide.

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Product Notices

  1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  2. Researchers should determine the optimal concentration of this reagent for their individual applications.
  3. An isotype control should be used at the same concentration as the antibody of interest.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at
  6. Please refer to for technical protocols.
  7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  8. Please refer to to access safety data sheets (SDS).
  9. Pacific Blue™ is a trademark of Life Technologies Corporation.
  10. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
  11. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit
753188 Rev. 1
Antibody Details
Down Arrow Up Arrow

The 13E11 monoclonal antibody specifically binds to CC chemokine receptor-like 1 (CCRL1) that is also known as C-C chemokine receptor type 11 (C-C CKR-11), or ChemoCentryx chemokine receptor (CCX-CKR). CCRL1 is a seven-transmembrane glycoprotein receptor that is encoded by ACKR4 (Atypical chemokine receptor 4) which belongs to the atypical chemokine receptor subfamily within the chemokine receptor superfamily. CCRL1 is expressed on stromal cells of lymph nodes, dermal lymphatic endothelial cells, and thymic epithelial cells. CCRL1 binds to several "homeostatic" chemokines including CCL19 (ELC), CCL21 (SLC), CCL25 (TECK) and CXCL13 (BLC) that can otherwise bind to functional chemokine receptors like CCR7, CCR9 or CXCR5. CCRL1 can thus serve as a decoy receptor that allows cellular uptake and degradation of these chemokines in a G protein-independent manner. This receptor may shape chemokine gradients in tissues by scavenging chemokines and thereby regulate the chemotaxis of thymic precursor cells, various leucocytes, including lymphocytes and dendritic cells, and cancer cells. CCRL1 expression is upregulated on some breast and hepatic cancer cell lines. The 13E11 antibody reportedly has ligand-like activity that results in the cellular internalization of CCRL1.  This antibody recognizes an epitope in the N-terminus of the first extracellular domain of CCRL1.

753188 Rev. 1
Format Details
Down Arrow Up Arrow
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Violet 405 nm
407 nm
423 nm
753188 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "753188" on CiteAb

Development References (4)

  1. Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.. Pharmacol Rev. 2014; 66(1):1-79. (Biology). View Reference
  2. Bryce SA, Wilson RA, Tiplady EM, et al. ACKR4 on Stromal Cells Scavenges CCL19 To Enable CCR7-Dependent Trafficking of APCs from Inflamed Skin to Lymph Nodes.. J Immunol. 2016; 196(8):3341-53. (Clone-specific: Fluorescence microscopy, Immunofluorescence). View Reference
  3. Takatsuka S, Sekiguchi A, Tokunaga M, Fujimoto A, Chiba J. Generation of a panel of monoclonal antibodies against atypical chemokine receptor CCX-CKR by DNA immunization.. J Pharmacol Toxicol Methods. 63(3):250-7. (Immunogen: Blocking, Cytotoxicity, Flow cytometry, Fluorescence microscopy, Functional assay, Immunofluorescence). View Reference
  4. Watts AO, Verkaar F, van der Lee MM, et al. β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR.. J Biol Chem. 2013; 288(10):7169-81. (Biology). View Reference
View All (4) View Less
753188 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.